SEC Form 4 · accession 0000886163-17-000106
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy Ryan Gray
Director
Period of report
Aug 18, 2017
Accepted (ET)
Aug 22, 2017 · 12:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 18, 2017 | A | 913 | $0.00 | A | 913 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | $126.26 | Aug 18, 2017 | A | 3,452 | A | Aug 18, 2018 | Aug 18, 2027 | Common Stock | 3,452 | 3,452 | D |
Explanation of responses
- F1Non-Qualified Stock Option (right to buy)
- F2The option becomes exercisable in 3 successive equal annual installments upon completion of each calendar year of service beginning on the grant date.